
### ü´† Heart Failure: Diagnostic Role of BNP in Dyspnea Evaluation

#### ‚úÖ True Statements
1. **B-type natriuretic peptide (BNP)** and **N-terminal pro‚ÄìB-type natriuretic peptide (NT-proBNP)** can help differentiate **heart failure** from **pulmonary and other noncardiac causes** in patients presenting with **dyspnea of unknown etiology**.
2. **BNP levels >400 pg/mL (400 ng/L)** have a **sensitivity of 95% to 97%** for diagnosing **heart failure**.
3. **BNP levels <100 pg/mL (100 ng/L)** have a **negative predictive value of 90% to 97%** for excluding **heart failure**.
4. **BNP levels** are typically **elevated** in **heart failure with elevated filling pressures** and **low to normal** in **pulmonary disease**.
5. Factors that may **increase BNP levels** include **older age**, **female sex**, **worsening kidney function**, and **sepsis**.
6. Factors that may **decrease BNP levels** include **obesity**.
7. **High-sensitivity cardiac troponin** levels may be **mildly increased** in **acute heart failure** due to **myocardial strain**, but are not optimal for differentiating causes of dyspnea.
8. **D-dimer testing** is not indicated in patients who meet **Pulmonary Embolism Rule-out Criteria (PERC)**.
9. A **high-resolution chest CT scan** is appropriate if **parenchymal lung disease** is suspected, but is not preferred in cases with **normal lung examination and imaging** findings.

#### üí¨ Extra
1. BNP and NT-proBNP are elevated in response to **increased myocardial wall stretch** caused by **volume or pressure overload**.
2. Intermediate BNP levels between **100‚Äì400 pg/mL** are diagnostically ambiguous and should be interpreted in clinical context.
5. **Angiotensin receptor‚Äìneprilysin inhibitor (ARNI)** therapy also increases BNP levels by reducing BNP degradation.
8. PERC includes: **age <50 years**, **heart rate <100 bpm**, **O‚ÇÇ saturation >95%**, **no estrogen use**, **no unilateral leg swelling**, **no prior PE/DVT**, **no recent surgery or trauma**, and **no hemoptysis**.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #HeartFailure #BNP #NTproBNP #PulmonaryEmbolism #DiagnosticTesting #Dyspnea

#### üìô Reference
Alcidi G, Goffredo G, Correale M, et al. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. *J Clin Med*. 2022;11. PMID: 35683578 doi:10.3390/jcm11113192

#### üÜî Question ID
CVMCQ24088

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Heart Failure, Diagnosis and Evaluation of Heart Failure, Diagnosis of Heart Failure

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Initial diagnostic testing for **heart failure** includes **electrocardiogram (ECG)**, **chest radiography**, and **laboratory studies**.
2. **Chest radiography** in heart failure may reveal **cardiomegaly**, **vascular congestion**, **Kerley B lines**, and **pleural effusions**.
3. **BNP levels** tend to be **lower in heart failure with preserved ejection fraction (HFpEF)** than in **heart failure with reduced ejection fraction (HFrEF)**.
4. **NT-proBNP <300 pg/mL** makes **heart failure very unlikely**.
5. **Age-specific NT-proBNP thresholds** for diagnosing heart failure are:   - **>450 pg/mL** for age <50 years   - **>900 pg/mL** for age 50‚Äì75 years   - **>1800 pg/mL** for age >75 years
6. **Laboratory evaluation** for heart failure should include **complete blood count**, **electrolytes**, **kidney function**, **glucose**, **lipid panel**, **liver chemistries**, **iron studies**, and **thyroid-stimulating hormone (TSH)**.
7. **Echocardiography** is the primary modality for evaluating **systolic and diastolic function**, **chamber size**, and **valvular disease** in heart failure.
8. **Cardiac magnetic resonance imaging (MRI)** is used to assess for **myocarditis**, **amyloidosis**, **sarcoidosis**, and **hypertrophic cardiomyopathy** when echocardiography is inconclusive.
9. **Elevated left ventricular (LV) filling pressures** can be documented by **BNP/NT-proBNP levels**, **echocardiographic criteria**, or **invasive hemodynamics**.

#### üí¨ Extra
3. BNP may be less elevated in HFpEF due to **lower LV wall stress** compared to HFrEF.
6. **TSH** is used to evaluate for **thyroid-related heart failure**, and **iron studies** assess for **hemochromatosis**.
9. **LV filling pressure elevation** is a diagnostic criterion for **HFpEF**, **HFmrEF**, and **HFrEF**.

#### üî∑ Tags
#HeartFailure #BNP #NTproBNP #HFpEF #HFrEF #CardiacImaging #DiagnosticTesting #Echocardiography #CardiacMRI #TSH #IronStudies #LeftVentricularFunction

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="CXR Decompensated Heart Failure.jpg" alt="Chest Radiograph Showing Decompensated Heart Failure">
  <figcaption>
    <strong>Chest Radiograph Showing Evidence of Decompensated Heart Failure</strong><br>
    Chest radiograph showing evidence of decompensated heart failure with pulmonary edema characterized by diffuse increased interstitial opacities, including Kerley B lines; prominent and indistinct pulmonary vasculature; and tiny pleural effusions.
  </figcaption>
</figure>

---

### üìä Supplemental Table

<!-- Other Causes of Heart Failure and Clinical Markers -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%; max-width:900px;">
  <caption style="font-weight:bold; text-align:left; padding-bottom:8px;">
    Other Causes of Heart Failure and Clinical Markers
  </caption>
  <thead style="background-color:#e8e8e8;">
    <tr>
      <th style="text-align:left; width:25%;">Cause</th>
      <th style="text-align:left;">Clinical Markers</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cardiotoxins</td>
      <td>
        Clinical history of cancer treated with chemotherapy<br>
        Treatment with hydroxychloroquine, stimulants for ADHD
      </td>
    </tr>
    <tr>
      <td>Rheumatologic</td>
      <td>History</td>
    </tr>
    <tr>
      <td>Familial</td>
      <td>History: at least three generations</td>
    </tr>
    <tr>
      <td>Infectious</td>
      <td>History of HIV, COVID-19, Chagas disease</td>
    </tr>
    <tr>
      <td>Tachycardia</td>
      <td>Either supraventricular (atrial arrhythmia with persistent tachycardia) or PVC mediated (&gt;10 % ectopic beats on ambulatory ECG)</td>
    </tr>
    <tr>
      <td>Amyloid</td>
      <td>LVH on echo with low voltage on ECG, neuropathy, carpal tunnel syndrome</td>
    </tr>
    <tr>
      <td>Other infiltrative</td>
      <td>Clinical suggestions for hemochromatosis (new-onset diabetes, skin bronzing), sarcoid (AV block, arrhythmias, lymphadenopathy)</td>
    </tr>
    <tr>
      <td>Peripartum</td>
      <td>History</td>
    </tr>
    <tr>
      <td>Stress cardiomyopathy</td>
      <td>History of emotionally or physically stressful event (high catecholamine state)</td>
    </tr>
    <tr>
      <td>Substance use</td>
      <td>History of alcohol, cocaine, methamphetamine use</td>
    </tr>
    <tr>
      <td>Autoimmune</td>
      <td>Patients with cancer who are receiving immune checkpoint inhibitors such as pembrolizumab</td>
    </tr>
  </tbody>
</table>
<p style="font-size:smaller;">
  <em>ADHD = attention-deficit/hyperactivity disorder; AV = atrioventricular; LVH = left ventricular hypertrophy; PVC = premature ventricular contraction.</em>
</p>
